Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Bone density in proton pump inhibitors users: a prospective study.

Ozdil K, Kahraman R, Sahin A, Calhan T, Gozden EH, Akyuz U, Erer B, Sokmen MH.

Rheumatol Int. 2013 Sep;33(9):2255-60. doi: 10.1007/s00296-013-2709-0. Epub 2013 Mar 2. Erratum in: Rheumatol Int. 2016 Oct;36(10):1479.

PMID:
23455632
2.

Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors.

Bahtiri E, Islami H, Hoxha R, Qorraj-Bytyqi H, Rexhepi S, Hoti K, Thaçi K, Thaçi S, Karakulak Ç.

J Bone Miner Metab. 2016 Sep;34(5):571-9. doi: 10.1007/s00774-015-0699-6. Epub 2015 Jul 25.

PMID:
26209167
3.

Proton pump inhibitors use and change in bone mineral density.

Arj A, Razavi Zade M, Yavari M, Akbari H, Zamani B, Asemi Z.

Int J Rheum Dis. 2016 Sep;19(9):864-8. doi: 10.1111/1756-185X.12866. Epub 2016 May 31.

PMID:
27242025
4.

Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.

Çelebi A, Aydın D, Kocaman O, Konduk BT, Şentürk Ö, Hülagü S.

Turk J Gastroenterol. 2016 Sep;27(5):408-414. doi: 10.5152/tjg.2016.15514.

5.

The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).

Targownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, Josse RG, Kaiser SM, Kovacs CS, Prior JC, Zhou W; CaMos Research Group.

Am J Gastroenterol. 2012 Sep;107(9):1361-9. doi: 10.1038/ajg.2012.200. Epub 2012 Jul 10. Erratum in: Am J Gastroenterol. 2013 Jan;108(1):157.

6.

Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.

Higginbotham TW.

Ann Pharmacother. 2010 Mar;44(3):572-6. doi: 10.1345/aph.1M519. Epub 2010 Feb 2. Review.

PMID:
20124466
7.

Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system.

Vasiliadis KV, Viazis N, Vlachogiannakos J, Sgouros SN, Stefanidis G, Archimandritis A, Karamanolis DG.

Am J Gastroenterol. 2010 Feb;105(2):308-13. doi: 10.1038/ajg.2009.556. Epub 2009 Oct 6.

PMID:
19809412
8.
9.

The innovative potential of Lactobacillus rhamnosus LR06, Lactobacillus pentosus LPS01, Lactobacillus plantarum LP01, and Lactobacillus delbrueckii Subsp. delbrueckii LDD01 to restore the "gastric barrier effect" in patients chronically treated with PPI: a pilot study.

Del Piano M, Anderloni A, Balzarini M, Ballarè M, Carmagnola S, Montino F, Orsello M, Pagliarulo M, Tari R, Soattini L, Sforza F, Mogna L, Mogna G.

J Clin Gastroenterol. 2012 Oct;46 Suppl:S18-26. doi: 10.1097/MCG.0b013e318267b55d.

PMID:
22955351
10.

Proton pump inhibitor omeprazole use is associated with low bone mineral density in maintenance haemodialysis patients.

Kirkpantur A, Altun B, Arici M, Turgan C.

Int J Clin Pract. 2009 Feb;63(2):261-8. doi: 10.1111/j.1742-1241.2008.01883.x.

PMID:
19196364
11.

Correlation of Bone Mineral Density Scores and Proton Pump Inhibitors Use in the Elderly.

Amoako AO, Jafilan L, Nasiri P, Pujalte GG.

Curr Rheumatol Rev. 2016;12(2):162-6.

PMID:
26496778
12.

Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.

Roux C, Goldstein JL, Zhou X, Klemes A, Lindsay R.

Osteoporos Int. 2012 Jan;23(1):277-84. doi: 10.1007/s00198-011-1574-5. Epub 2011 Mar 2.

PMID:
21365461
13.

Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study.

Jonasson C, Tvete IF, Hatlebakk JG.

Scand J Gastroenterol. 2013 Sep;48(9):1010-7. doi: 10.3109/00365521.2013.812140. Epub 2013 Jul 16.

PMID:
23859491
14.

Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease.

Tjon JA, Pe M, Soscia J, Mahant S.

Pharmacotherapy. 2013 Sep;33(9):956-71. doi: 10.1002/phar.1299. Epub 2013 May 26. Review.

PMID:
23712734
15.

Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.

Targownik LE, Lix LM, Leung S, Leslie WD.

Gastroenterology. 2010 Mar;138(3):896-904. doi: 10.1053/j.gastro.2009.11.014. Epub 2009 Nov 18.

PMID:
19931262
17.

Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.

Solomon DH, Diem SJ, Ruppert K, Lian YJ, Liu CC, Wohlfart A, Greendale GA, Finkelstein JS.

J Bone Miner Res. 2015 Feb;30(2):232-9. doi: 10.1002/jbmr.2344.

18.

Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?

de Bortoli N, Martinucci I, Savarino E, Bellini M, Bredenoord AJ, Franchi R, Bertani L, Furnari M, Savarino V, Blandizzi C, Marchi S.

Neurogastroenterol Motil. 2014 Jan;26(1):28-35. doi: 10.1111/nmo.12221. Epub 2013 Aug 29.

PMID:
23992024
19.

[What is the utility of proton pump inhibitor testing in non-cardiac chest pain?].

Huamán JW, Aliaga V, Domenech G, Videla S, Saperas E.

Gastroenterol Hepatol. 2014 Oct;37(8):452-61. doi: 10.1016/j.gastrohep.2014.02.009. Epub 2014 Apr 13. Spanish.

PMID:
24725608
20.

Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.

Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z.

Arch Intern Med. 2010 May 10;170(9):765-71. doi: 10.1001/archinternmed.2010.94.

Supplemental Content

Support Center